Allergan rolls out third round of Linzess ads

Allergan ($AGN) has already launched two DTC campaigns for its GI med Linzess. In its third push, the company is putting patients front and center, highlighting individual stories to tout the drug's advantages over OTC therapies.

Allergan's new DTC ads feature patients who have tried and failed to find relief for irritable bowel syndrome and constipation (IBS-C) or chronic constipation by using over-the-counter therapies. "Try laxatives," one man scoffs. "Been there, done that," he says, standing in a pharmacy aisle. "My chronic constipation keeps coming back," a woman says. "I know. Tell me something I don't know." The ad ends with an orange plane flying overhead with flag with the word "proactively."

"Linzess is a way to proactively manage the condition. We've been delivering this message since launch and I believe that it's working," Allergan VP of Branded Pharma Marketing Bill Meury said. "We've converted close to 10% of the OTC market."

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

At least so far, the company's hard work seems to be paying off. In the last 30 days, Linzess commercials have aired 893 times, with the brand earning an airing ranking of 777 and a spend ranking of 225 compared to other advertisers, according to iSpot data.

The drug, which launched in 2012, is also raking in some serious cash for Allergan. Linzess brought in $131 million in global sales in Q4 2015. That number was "driven by strong OTC conversion momentum and enhanced presence in long-term care market," the company said in a Q4 earnings statement.

But Allergan is far from finished. About 100,000 physicians are prescribing the product now, and over the next two years that number will double, Meury predicted. "The campaign reflects the size of the category and the number of potential users," he said.

Allergan is also putting a strong sales force behind the latest DTC campaign. The company has about 1,500 reps promoting the drug to primary care physicians, gastroenterologists and long-term care facilities.

Bill Meury

Meanwhile, Allergan will continue to work on developing Linzess. The drug "has a long exclusivity period and we're developing a low-dose version and looking at new indications," Meury said. "It's a very important product for Allergan and it will continue to be an important product when we close our merger with Pfizer."

- watch the commercial

Special Report: Top 10 DTC Pharma Advertisers - H1 2013

Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Roche’s targeted cancer drug Rozlytrek is officially cleared for a U.S. launch—and in not one, but two indications.

Amarin may still be waiting for the FDA to include new risk-reduction info to Vascepa's label, but in the meantime, it's getting prepared.